|
zu MRKR - neue Studienergebnisse. "We continue to be highly encouraged by the clinical results we've seen to date with our MultiTAA therapies. In AML, we believe we are seeing increasing evidence of meaningful therapeutic benefit for patients with limited treatment alternatives. Our MultiTAA therapy appears to be safe and well-tolerated with the potential to mediate a meaningful anti-tumor effect, in addition to demonstrating a compelling correlation between therapeutic responses, with superior in vivo expansion of our T cells," said Peter L. Hoang, President & CEO of Marker Therapeutics. "Similarly, the studies ongoing in acute lymphoblastic leukemia, or ALL, lymphoma and multiple myeloma continue to demonstrate positive results, and are supportive of the data we presented at ASH in December, importantly with no additional disease relapses. Overall, this data update and our update at ASH 2018 in December collectively have increased our total reported number of patients to 78 as compared to the 57 patients we had reported as of November." AML Study Results In Arm A of the AML study, 13 patients at Baylor College of Medicine were dosed with MultiTAA T cells as a maintenance therapy after receiving allogeneic stem cell transplant. Results demonstrated: 11 out of 13 patients remain alive, ranging from 6 weeks to 2.5 years post-infusion. Nine of these patients have never relapsed after MultiTAA therapy and continue to remain in complete remission (CR), durable between 6 weeks to 2.5 years; Two patients saw local relapse in the central nervous system, but in both cases these patients were successfully treated with local therapy alone; One patient saw extramedullary relapse and was subsequently treated in the active disease arm (Arm B) of the trial, generating a CR that was durable for 13 months; and One patient relapsed 8 months after receiving MultiTAA T cells but following a second allogeneic stem cell transplant this patient remains alive in relapse 1.5 years following his initial T cell infusion. In Arm B of the AML study, 6 patients suffering from active disease with relapsed/refractory (r/r) AML have been treated, with 1 patient having been treated twice for active disease with MultiTAA T cells; 2 patients were non-responsive to MultiTAA therapy and progressed with r/r disease; 1 patient developed a complete response (CR), which was durable for 13 months; and 1 patient developed a partial response (PR) that enabled that patient to receive a second allogeneic stem cell transplant; The patient who developed a partial response saw significant tumor debulking, with circulating blasts reduced from over 50% to 15%. 2 additional patients who did not meet partial response criteria experienced disease stabilization enabling a 2-month delay to next-line therapy Of these patients with disease stability, one patient was sufficiently stabilized to enable that patient to receive a second allogeneic stem cell transplant. The second transplant eliminated the patient's MultiTAA T cells. This patient was given a second dose of MultiTAA T cells after initial disease relapse after the second transplant, but progressed to another line of therapy prior to any evaluable response assessment to the subsequent dose of MultiTAA T cells; The other patient who had disease stability saw significant reduction in tumor burden, with a reduction in circulating blasts from 70% prior to infusion of MultiTAA T cells, to approximately 45% circulating blasts after MultiTAA therapy. For patients in Arm B, overall survival ranged from 4 to 21 months after T cell infusions. ALL Results In addition to data from ongoing lymphoma and multiple myeloma trials, also presented in an oral presentation at the meeting were updated results from an ongoing study in ALL. Updates from this trial included: Patients are now up to 28 months in CCR (Continued Complete Remission); The only patient who has experienced relapse was a patient who displayed mixed donor/recipient chimerism after transplant, but remained in CCR for 6 months prior to relapse; Patients that remain in CCR have been durable for between 4 to 28 months, with a median duration of 16 months. "We are very excited about the results we are seeing in our early clinical trials. For patients with r/r AML, we believe that MultiTAA therapies may produce meaningful improvements in overall survival of patients who historically have had a dire prognostic outlook," stated Mythili Koneru, Senior Vice President of Clinical Development at Marker Therapeutics. "In adjuvant settings for patients currently in remission, I believe our early clinical results suggest that we may be providing significant additional protection against relapse and disease recurrence." |
|
| aus der Diskussion: | Gewinnerbranchen der Jahre 2006 bis 2040 |
| Autor (Datum des Eintrages): | clearasil (25.02.19 16:26:41) |
| Beitrag: | 85,055 von 94,068 (ID:59957731) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |